# Uterine Inflammatory Myofibroblastic Tumor Mimicking Myoma Treated With Gonadotropin-Releasing Hormone Therapy: A Case Report

**Authors:** Kenji Yorita, Koki Hirano, Kimiko Nakatani

PMC · DOI: 10.7759/cureus.84722 · 2025-05-24

## TL;DR

A rare uterine tumor was mistaken for a myoma and successfully treated with GnRH therapy, showing shrinkage before surgery.

## Contribution

First reported case of uterine IMT responding to GnRH therapy and highlighting diagnostic challenges.

## Key findings

- GnRH therapy led to a reduction in the size of the largest uterine mass from 81 mm to 62 mm over four months.
- Histopathology confirmed the tumor was an IMT with ALK positivity and gene rearrangement.
- The remaining masses were diagnosed as typical leiomyomas, showing the difficulty in preoperative differentiation.

## Abstract

Inflammatory myofibroblastic tumors (IMTs) of the uterus are a rare entity that can be challenging to distinguish from leiomyomas, both radiologically and pathologically. No previous reports have documented the response of uterine IMT to gonadotropin-releasing hormone (GnRH) therapy. A 47-year-old Japanese woman presented to our hospital with excessive menstruation and uterine prolapse. Magnetic resonance imaging (MRI) revealed four well-demarcated uterine masses, with the largest measuring 81 mm. Myomas were suspected. Oral GnRH therapy was initiated to relieve the symptoms and reduce the preoperative volume. After four months, follow-up MRI showed a reduction in the largest mass to 62 mm and increased hyperintense areas on T2-weighted images. At six months, the patient underwent laparoscopic hysterectomy and colporrhaphy. Histopathological examination revealed that the largest tumor was an IMT with abundant myxoid matrix, positive for anaplastic lymphoma kinase (ALK), and ALK gene rearrangement. The remaining three masses were diagnosed as usual-type leiomyomas. This is the first reported case of uterine IMT treated with GnRH therapy, which resulted in notable tumor shrinkage. This case highlights both the potential therapeutic approach for uterine IMT and the diagnostic difficulty in distinguishing it from leiomyomas preoperatively.

## Linked entities

- **Genes:** ALK (ALK receptor tyrosine kinase) [NCBI Gene 238]
- **Diseases:** inflammatory myofibroblastic tumor (MONDO:0015798)

## Full-text entities

- **Genes:** ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}, GNRH1 (gonadotropin releasing hormone 1) [NCBI Gene 2796] {aka GNRH, GRH, LHRH, LNRH}
- **Diseases:** masses (MESH:C536030), IMTs (MESH:D009369), uterine prolapse (MESH:D014596), Inflammatory (MESH:D007249), leiomyomas (MESH:D007889), Myoma (MESH:D009214), Uterine (MESH:D014591)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12185251/full.md

---
Source: https://tomesphere.com/paper/PMC12185251